HUTCHMED (China) Limited (HK:0013)
:0013
Want to see HK:0013 full AI Analyst Report?
Top Page
HUTCHMED (China)
(0013)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$19.00
▼(-10.29% Downside)
Action:Reiterated
Date:03/07/26
The score is held back mainly by weak cash generation and negative operating profitability in 2025, despite a conservatively levered balance sheet. Technicals also signal a continuing downtrend (below major DMAs, negative MACD). Valuation is a relative positive due to the low P/E, but it does not fully offset the operating and cash-flow concerns.
Positive Factors
Balance Sheet Strength
A conservatively levered balance sheet and expanding equity base provide durable financial flexibility for a biotech: supports continued R&D and commercialization spending, reduces refinancing risk during cash fluctuations, and allows the company to pursue partnerships or bridge temporary cash shortfalls without immediate dilution.
Negative Factors
Weak Cash Generation
Repeated swings to negative operating and free cash flow reduce runway and force reliance on external funding or asset monetization. For a development-stage biopharma, persistent cash burn constrains sustained R&D, commercialization scaling, and increases dilution or refinancing risk if operating performance does not normalize.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A conservatively levered balance sheet and expanding equity base provide durable financial flexibility for a biotech: supports continued R&D and commercialization spending, reduces refinancing risk during cash fluctuations, and allows the company to pursue partnerships or bridge temporary cash shortfalls without immediate dilution.
Read all positive factors
HUTCHMED (China) (0013) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.52B
Dividend YieldN/A
Average Volume (3M)7.40M
Price to Earnings (P/E)51.5
Beta (1Y)0.83
Revenue Growth-13.04%
EPS Growth1113.58%
CountryHK
Employees1,811
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.54
Shares Outstanding872,335,140
10 Day Avg. Volume5,279,510
30 Day Avg. Volume7,396,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.88
Price to Sales (P/S)4.24
P/FCF Ratio-29.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$30.94Price Target Upside46.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$638.75M
HUTCHMED (China) Business Overview & Revenue Model
Company Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...
How the Company Makes Money
HUTCHMED primarily makes money through (1) product sales of its commercial-stage medicines and (2) collaboration income from partnerships.
1) Product sales (commercial revenue): The company generates revenue by selling its approved prescription d...
HUTCHMED (China) Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 548.51M | 630.20M | 838.00M | 426.41M | 356.13M |
| Gross Profit | 63.87M | 281.32M | 151.55M | 115.31M | 97.89M |
| EBITDA | -25.85M | 14.11M | 67.27M | -401.11M | -321.13M |
| Net Income | 456.91M | 37.73M | 100.78M | -360.83M | -194.65M |
Balance Sheet | |||||
| Total Assets | 1.75B | 1.27B | 1.28B | 1.03B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 836.11M | 886.34M | 631.00M | 1.01B |
| Total Debt | 97.88M | 89.82M | 86.13M | 27.01M | 38.98M |
| Total Liabilities | 501.77M | 502.34M | 536.39M | 392.57M | 333.15M |
| Stockholders Equity | 1.24B | 759.93M | 730.54M | 610.37M | 986.89M |
Cash Flow | |||||
| Free Cash Flow | -78.92M | -17.44M | 186.65M | -305.26M | -220.98M |
| Operating Cash Flow | -64.75M | 497.00K | 219.26M | -268.60M | -204.22M |
| Investing Cash Flow | -29.45M | -96.06M | -291.14M | 296.59M | -306.32M |
| Financing Cash Flow | 7.85M | -30.67M | 48.66M | -82.76M | 650.03M |
HUTCHMED (China) Technical Analysis
Negative
21.18
Price Trends
21.54
Negative
22.26
Negative
23.12
Negative
Market Momentum
-0.98
Positive
29.86
Positive
16.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0013, the sentiment is Negative. The current price of 21.18 is above the 20-day moving average (MA) of 19.73, below the 50-day MA of 21.54, and below the 200-day MA of 23.12, indicating a bearish trend. The MACD of -0.98 indicates Positive momentum. The RSI at 29.86 is Positive, neither overbought nor oversold. The STOCH value of 16.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0013.
HUTCHMED (China) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$28.32B | 13.95 | 13.95% | 4.09% | 1.48% | -1.55% | |
72 Outperform | HK$190.41B | 29.32 | 16.71% | 0.97% | 22.62% | 26.23% | |
63 Neutral | HK$25.22B | 14.84 | 8.60% | 2.26% | 10.00% | -7.54% | |
58 Neutral | HK$64.79B | 17.65 | 7.19% | 1.69% | 1.52% | 22.54% | |
55 Neutral | HK$15.52B | 51.55 | 37.04% | ― | -13.04% | 1113.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$11.03B | -14,376.22 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:0013
HUTCHMED (China)
18.32
-4.13
-18.40%
HK:0867
China Medical System Holdings
10.58
0.12
1.19%
HK:1513
Livzon Pharmaceutical Group
26.28
-1.71
-6.10%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.02
0.90
5.56%
HK:3692
Hansoh Pharmaceutical Group Company Limited
31.44
5.88
23.00%
HK:6185
CanSino Biologics, Inc. Class H
25.82
-7.98
-23.61%
HUTCHMED (China) Corporate Events
HUTCHMED Publishes 2025 Annual Report and Sets Hybrid 2026 AGM
Apr 9, 2026
HUTCHMED (China) Limited has released its 2025 Annual Report along with the Notice of Annual General Meeting and Form of Proxy, making the materials available both in printed form for electing shareholders and online via its corporate website. The...
HUTCHMED Sets 2026 AGM With New Share Issuance and Buyback Mandates
Apr 9, 2026
HUTCHMED (China) Limited has called its 2026 annual general meeting for May 12, 2026 in Hong Kong as a hybrid event with both physical and electronic participation options for shareholders. The agenda includes adoption of the 2025 audited financia...
HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026
Apr 9, 2026
HUTCHMED announced that it will present new preclinical and clinical data at the American Association for Cancer Research Annual Meeting 2026, highlighting advances from its in-house oncology pipeline. The data include preclinical results for HMPL...
HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients
Mar 23, 2026
HUTCHMED has begun a registrational Phase III clinical trial in China of its investigational BTK inhibitor HMPL-760 combined with R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for transplantation....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.